Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Part of paid clinical trials in Pasadena, California.

Sponsor
Kaiser Permanente
Study ID
NCT05073692
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • SU — DRUG
    Exposure to the class of drugs known as Sulfonylureas (SU)
  • DPP4 — DRUG
    Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
  • SGLT2i — DRUG
    Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
  • GLP-1RA — DRUG
    Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
  • SGLT2i or GLP-1RA — DRUG
    Exposure to either SGLT2i or GLP-1RA
  • Linagliptin (DPP4) — DRUG
    Exposure to agent Linagliptin (DPP4)
  • Exenatide (GLP-1RA) — DRUG
    Exposure to agent Exenatide (GLP1-RA)
  • Liraglutide (GLP-1RA) — DRUG
    Exposure to agent Liraglutide (GLP-1RA)
  • Empagliflozin (SGLT2i) — DRUG
    Exposure to agent Empagliflozin (SGLT2i)
  • Glimepiride (SU) — DRUG
    Exposure to agent Glimepiride (SU)
  • Glipizide (SU) — DRUG
    Exposure to Glimepiride (SU)
  • Glimepiride (SU) or Glipizide (SU) — DRUG
    Exposure to agent Glimepiride (SU) or Glipizide (SU)
  • SU or DPP4 (excluding saxagliptin and alogliptin) — DRUG
    Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
  • Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) — DRUG
    Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)

Study Details

This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.

Key Dates

Start date
Jul 1, 2021
Status verified
Nov 2025
Primary completion
Dec 31, 2024
Completion
Mar 12, 2025

Study Design

Enrollment
241,981 participants (actual)

Primary Outcome Measure

Incidence of 3-point Major Adverse Cardiovascular Events (MACE) [ Time Frame: 2.5 years ]

Locations (6)

FacilityCityStateZIPSite coordinators
Kaiser Permanente Southern CaliforniaPasadenaCalifornia91101-
Romain S. NeugebauerPleasantonCalifornia94588-
Kaiser Permanente HawaiiHonoluluHawaii96817-
Henry Ford Health SystemDetroitMichigan48202-
HealthPartners InstituteBloomingtonMinnesota55425-
GeisingerDanvillePennsylvania17821-

Related coverage on Hipa.ai

Find similar trials in Pasadena, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Kaiser Permanente Southern California· Pasadena, CARomain S. Neugebauer· Pleasanton, CAKaiser Permanente Hawaii· Honolulu, HIHenry Ford Health System· Detroit, MIHealthPartners Institute· Bloomington, MNGeisinger· Danville, PA

Related Studies